Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the company’s shares.

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has ...

Abbott forecast current-quarter profit below estimates after missing Wall Street expectations for quarterly revenue on ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter earnings that met expectations but missed on revenue, sending shares down 4.8% as investors reacted to the shortfall and weaker-than-expected ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...

Abbott Laboratories reported fourth quarter sales below expectations before the market opened on Jan. 22, sending the stock down nearly 12% from the prior day's closing. The biggest hits came from ...

In the fourth quarter, Abbott’s sales were $11.5 billion, below the average analyst estimate of $11.8 billion. Nutrition sales were $1.9 billion, far short of the average analyst estimate of $2.19 ...

Abbott Laboratories (NYSE:ABT) shares fell about 4.8% after the company reported fourth-quarter results that met earnings ...